BackNeuBase Therapeutics Overview

NeuBase Therapeutics Current Cash

Track NeuBase Therapeutics's current cash ($13M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$12.57M
↓ 45.71% YoYΔ $-10.58M vs prior year quarter

Peer average

Loading

NeuBase Therapeutics Current Cash History

Loading

NeuBase Therapeutics vs. peers: Current Cash Comparison

Loading

NeuBase Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

NeuBase Therapeutics (NBSE) FAQ

NeuBase Therapeutics (NBSE) currently reports a current cash of $13M as of September 2023. That compares with $23M in the prior-year period — down 45.7% year over year. Use the charts on this page to explore NeuBase Therapeutics's current cash history and peer comparisons.

NeuBase Therapeutics's current cash decreased from $23M to $13M — a 45.7% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NeuBase Therapeutics reported $13M in current cash as of September 2023. That compares with $23M in the prior-year period — down 45.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $13M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for NeuBase Therapeutics, and consider following NBSE for alerts when major investors trade the stock.

NeuBase Therapeutics is classified in the Healthcare sector. On current cash, it currently shows $13M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NBSE with unrelated industries.